Future Outcomes of First-Line TNFi After Initial Nonresponse

A recent study conducted by experts in Rheumatology, including AARA’s John R. P. Tesser, MD, FACP, FACR, MACR, looked at patients with rheumatoid arthritis (RA) who started taking a medication used to treat RA, a tumor necrosis factor inhibitor (TNFi).

Overall, the study showed that if patients treated with a TNFi did not improve initially, they were unlikely to improve later, and that nearly a quarter of patients who improved initially with a TNFi saw their condition worsen.

Find the full publication here:
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States